Alfonso Soto Gonzalez

Dr. Alfonso Soto Gonzalez


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Nutrition
Verified
Journal Article
Closed access
AGAlfonso Soto Gonzalez
Alfonso Soto Gonzalez
DIEGO BELLIDO GUERRERODIEGO BELLIDO GUERRERO
DIEGO BELLIDO GUERRERO
MBMaría Manuela Buño
María Manuela Buño
SDSonia Pertega Diaz
Sonia Pertega Diaz
Daniel-Antonio de Luis RomanDaniel-Antonio de Luis Roman
Daniel-Antonio de Luis Roman
OVOvidio Vidal
Ovidio Vidal

3 August 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
IMIRENE CABALLERO MATEOS
IRENE CABALLERO MATEOS
MLMaria Dolores Garcia de Lucas
Maria Dolores Garcia de Lucas
VDViyey Kishore Doulatram-Gamgaram
Viyey Kishore Doulatram-Gamgaram
PMPaloma Moreno-Moreno
Paloma Moreno-Moreno
AJAna Isabel Jimenez-Millan
Ana Isabel Jimenez-Millan
Cristobal Jesus Morales PortilloCristobal Jesus Morales Portillo
Cristobal Jesus Morales Portillo
Although, in randomized clinical trials, once-weekly subcutaneous semaglutide (OW s.c.) has demonstrated superior efficacy in comparison with placebo and active controls in terms of glycemic control and body weight reduction in patients with type 2 diabetes mellitus (T2DM), these results need to be confirmed in a real-world (RW) setting. An RW ambispective study (6 months retrospective and 6 months prospective) was conducted in 10 tertiary hospitals in Spain. We evaluated changes in HbA1c and body weight in patients with T2DM treated with semaglutide OW s.c. Additionally, we analyzed different subgroups of patients treated with semaglutide OW s.c. as an add-on to glucose-lowering therapy. A total of 752 patients with a mean age of 60.2 years, a mean HbA1c level of 8.5%, a mean body weight of 101.6 kg, and a mean T2DM duration of 10 years were included. At 12 months, compared with baseline, there was a mean difference of −2.1% in HbA1c levels (p < 0.001) and a mean difference of 9.2 kg in body weight (p < 0.001). Moreover, there were statistically significant differences (p < 0.001) between baseline and month 12 in both HbA1c and body weight in the four subgroups receiving semaglutide OW s.c. as an add-on to glucose-lowering therapy. Semaglutide OW s.c. was well tolerated, with gastrointestinal disorders being the most commonly reported side effects. In this RW study, 12 months of treatment with semaglutide OW s.c. in patients with T2DM was associated with significant and clinically relevant improvements in glycemic control and weight loss, regardless of the glucose-lowering therapy received, and the overall safety profile was positive.